Genmab reports Phase 3 trial shows 50% death‑risk reduction for head‑and‑neck cancer combo

Genmab announced that its Phase 3 LiGeR‑HN1 study of petosemtamab combined with pembrolizumab met both primary endpoints in first‑line PD‑L1‑positive recurrent or metastatic head‑and‑neck squamous cell carcinoma. The trial showed a hazard ratio of 0.50 for overall survival and an odds ratio of 3.17 for tumor response, indicating a 50% lower risk of death versus pembrolizumab alone. Analysts upgraded the stock and raised price targets, while the share price jumped roughly 30% to a new 52‑week high.

Analysts now see a higher upside, with the consensus average price target lifted to $94.89, implying about 62% upside from the current price. The positive data could lead to regulatory submissions and future revenue streams if the drug gains approval.

  • 1The trial’s overall‑survival hazard ratio was 0.50.
  • 2The objective‑response odds ratio was 3.17.
  • 3The combination reduced the risk of death by 50% compared with pembrolizumab alone.
  • 4Genmab shares rose about 30% to $58.15 after the announcement.
  • 5The stock reached a 52‑week high of $57.60 during the session.
  • 6Trading volume spiked to 19.66 million shares, versus a three‑month average of about 4.14 million.

Sources